MY-943 is a potent inhibitor of tubulin polymerization and LSD1 with anti-cancer activity. MY-943 induces G2/M phase arrest and apoptosis, and inhibits cell migration, and may be utilized in gastric cancer research.

Physicochemical Properties

Molecular Formula	C30H36N4O6S2
Molecular Weight	612.76
Appearance	Light yellow to yellow solid powder
HS Tariff Code	2934.99.9001
Storage	Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Shipping Condition	Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

Biological Activity

ln Vitro	MY-943 exhibits anti-proliferative action against MGC-803 cells, HCT-116 cells, and KYSE450 cells, with IC50 values of 0.019 μM, 0.044 μM, and 0.030 μM, respectively [1]. MY-943 (10, 20, 30 nM; 20, 40, 48, and 60 h) suppresses MGC-803 and SGC-7901 cells' ability to proliferate in a dose- and time-dependent manner [1]. MY-943 (1, 5, 10 μM; 48 h) inhibits the formation of EBI adduct bands in MGC-803 and SGC-7901 cells and dose-dependently attenuates β-tubulin alkylation in the presence of EBI [1]. In MGC-803 and SGC-7901 cells, MY-943 (10, 20, 30 nM; 8, 16, 24 nM; 48 h) concentration-dependently suppresses tubulin polymerization [1]. In a dose-dependent manner, MY-943 (10, 20, 30 nM; 8, 16, 24 nM; 48 h) promotes apoptosis [1]. MY-943 elevates the expression levels of cleaved caspase-3 and caspase-7 in a dose-dependent manner while dose-dependently downregulating the expression levels of anti-apoptotic proteins Bcl-2 and Mcl-1 [1]. Weel, Cyclin B1, and CDC2 expression levels are dose-dependently down-regulated by MY-943 (10, 20, 30 nM; 8, 16, 24 nM; 48 h), while the expression levels of p-histone H3, H3K4me1, and H3K4me2 are dose-dependently increased[1]. G2/M phase arrest is potently and dose-dependently induced by MY-943 (10, 20, 30 nM; 8, 16, 24 nM; 48 h) [1]. The capacity of MY-943 (10, 20, 30 nM; 8, 16, 24 nM; 48 h) to strongly inhibit the migration of MGC-803 and SGC-7901 gastric cancer cells has been shown [1].
ln Vivo	MY-943 (25 mg/kg/day; i.p.; 21 days) dramatically decreased the weight and volume of tumor tissue in mice and significantly slowed the growth of gastric cancer in mice [1].
Cell Assay	Cell Viability Assay[1] Cell Types: MGC-803 and SGC-7901 cells Tested Concentrations: 10, 20, 30 nM Incubation Duration: 20, 40, 48, 60 h Experimental Results: Dose-dependently inhibited the cell viability of MGC-803 and Time-dependently inhibited the cell viability of MGC-803 and SGC-7901 cells(10, 20, 30 nM; 48 h). Western Blot Analysis[1] Cell Types: MGC-803 and SGC-7901 cells Tested Concentrations: 1, 5, 10 μM Incubation Duration: 48 h Experimental Results: Dose-dependently weakened the alkylation of β-tubulin in the presence of EBI, and prevented the formation of β-tubulin:EBI adduct band in MGC-803 and SGC-7901 cells. Immunofluorescence[1] Cell Types: MGC-803 and SGC-7901 cells Tested Concentrations: 10, 20, 30 nM for SGC-7901 cells; 8, 16, 24 nM for MGC-803 cells Incubation Duration: 48 h Experimental Results: Concentration-dependently inhibited tubulin polymerization in MGC-803 and SGC-7901 cells, thereby destroying the microtubule network. Immunofluorescence[1] Cell Types: MGC-803 and SGC- 7901 cells Tested Concentrations: 10, 20, 30 nM for SGC-7901 cells; 8, 16, 2
Animal Protocol	Animal/Disease Models: BALB/c-nu nude mice[1] Doses: 25 mg/kg Route of Administration: 25 mg/kg/day; ip; 21 days Experimental Results: Dramatically inhibited the growth of gastric cancer and greatly decreased the weight and volume of the tumor tissues.
References	[1]. Discovery of novel N-benzylarylamide-dithiocarbamate based derivatives as dual inhibitors of tubulin polymerization and LSD1 that inhibit gastric cancers. Eur J Med Chem. 2023 Apr 5;252:115281.

Solubility Data

Solubility (In Vitro)

May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples

Solubility (In Vivo)

Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples. Injection Formulations (e.g. IP/IV/IM/SC) Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] *Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Injection Formulation 5: 2-Hydroxypropyl-β-cyclodextrin : Saline = 50 : 50 (i.e. 500 μL 2-Hydroxypropyl-β-cyclodextrin → 500 μL Saline) Injection Formulation 6: DMSO : PEG300 : castor oil : Saline = 5 : 10 : 20 : 65 (i.e. 50 μL DMSO → 100 μLPEG300 → 200 μL castor oil → 650 μL Saline) Injection Formulation 7: Ethanol : Cremophor : Saline = 10： 10 : 80 (i.e. 100 μL Ethanol → 100 μL Cremophor → 800 μL Saline) Injection Formulation 8: Dissolve in Cremophor/Ethanol (50 : 50), then diluted by Saline Injection Formulation 9: EtOH : Corn oil = 10 : 90 (i.e. 100 μL EtOH → 900 μL Corn oil) Injection Formulation 10: EtOH : PEG300：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL EtOH → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Oral Formulations Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). Oral Formulation 3: Dissolved in PEG400 Oral Formulation 4: Suspend in 0.2% Carboxymethyl cellulose Oral Formulation 5: Dissolve in 0.25% Tween 80 and 0.5% Carboxymethyl cellulose Oral Formulation 6: Mixing with food powders Note: Please be aware that the above formulations are for reference only. InvivoChem strongly recommends customers to read literature methods/protocols carefully before determining which formulation you should use for in vivo studies, as different compounds have different solubility properties and have to be formulated differently.  (Please use freshly prepared in vivo formulations for optimal results.)

Preparing Stock Solutions		1 mg	5 mg	10 mg
	1 mM	1.6320 mL	8.1598 mL	16.3196 mL
	5 mM	0.3264 mL	1.6320 mL	3.2639 mL
	10 mM	0.1632 mL	0.8160 mL	1.6320 mL

*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.